Revolutionizing precision nutrition with gut microbiome insights

Researchers at Rutgers University-New Brunswick, along with international collaborators, have introduced a novel method for identifying the crucial set of gut microbes commonly found in humans and essential for health.

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) – Psychedelic Alpha

Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia DMX-1002 (Ibogaine)

August 10, 2023

GLP-1s lower risk of 10 obesity-associated cancers, study shows

New research finds that the GLP-1 class of drugs — glucagon-like peptide receptor agonists — is more effective in mitigating the risk of 10 obesity-associated

July 5, 2024

CytoReason secures $80m investment for AI expansion

The funding will aid CytoReason to expand disease models and proprietary data. Credit: PeopleImages.com – Yuri A / Shutterstock. CytoReason has secured $80m in funding

July 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.